Royal Bank of Canada
VTGN icon

Royal Bank of Canada’s VistaGen Therapeutics VTGN Stock Holding History

Royal Bank of Canada’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$0 Sell
500
-1,627
-76% -$981 ﹤0.01% 7851
2026
Q1 		$1K Buy
+2,127
New +$1.29K ﹤0.01% 6972
2025
Q3 		– Sell
-3,297
Closed -$7K – 7565
2025
Q2 		$7K Buy
3,297
+2,386
+262% +$5.42K ﹤0.01% 6581
2025
Q1 		$2K Sell
911
-948
-51% -$2.68K ﹤0.01% 6601
2024
Q4 		$5K Sell
1,859
-2,642
-59% -$7.43K ﹤0.01% 6553
2024
Q3 		$14K Buy
4,501
+3,420
+316% +$11.7K ﹤0.01% 6237
2024
Q2 		$4K Buy
+1,081
New +$4.68K ﹤0.01% 6627
2024
Q1 		– Sell
-1,437
Closed -$7K – 7652
2023
Q4 		$7K Sell
1,437
-1,423
-50% -$5.38K ﹤0.01% 6597
2023
Q3 		$15K Buy
2,860
+2,711
+1,819% +$12K ﹤0.01% 6292
2023
Q2 		$0 Sell
149
-237
-61% -$831 ﹤0.01% 7696
2023
Q1 		$1K Sell
386
-566
-59% -$2.97K ﹤0.01% 6942
2022
Q4 		$3K Buy
952
+873
+1,105% +$3.29K ﹤0.01% 6883
2022
Q3 		$0 Buy
79
+9
+13% +$89 ﹤0.01% 7914
2022
Q2 		$2K Sell
70
-327
-82% -$11.5K ﹤0.01% 7006
2022
Q1 		$15K Sell
397
-1,056
-73% -$46K ﹤0.01% 6769
2021
Q4 		$85K Buy
1,453
+791
+119% +$51.5K ﹤0.01% 6052
2021
Q3 		$55K Buy
662
+224
+51% +$19.5K ﹤0.01% 6106
2021
Q2 		$41K Buy
+438
New +$32.5K ﹤0.01% 6174
2020
Q2 		– Sell
-7
Closed – – 6935
2020
Q1 		$0 Hold
7
– – ﹤0.01% 7066
2019
Q4 		$0 Hold
7
– – ﹤0.01% 7149
2019
Q3 		$0 Buy
+7
New +$156 ﹤0.01% 7163

Other funds holding VTGN

CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
LM
Luminus Management Houston, Texas $146M AUM 27.83% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Royal Bank of Canada's VTGN Position: Q2 2026 in Review

Royal Bank of Canada reduced its VistaGen Therapeutics (VTGN) stake by 76% in Q2 2026, selling an estimated $981 and leaving 500 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #7851.

Royal Bank of Canada first reported a position in VTGN in Q3 2019 and has held it in 21 quarters since. The position peaked at $85K in Q4 2021. 48 funds tracked by Wall St. Rank hold VTGN as of Q2 2026.

  • Royal Bank of Canada held 500 shares of VistaGen Therapeutics worth $0 as of Q2 2026.
  • Royal Bank of Canada sold 1,627 VistaGen Therapeutics shares in Q2 2026, an estimated $981.
  • VistaGen Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q2 2026, its #7851 holding.
  • Royal Bank of Canada first reported a position in VistaGen Therapeutics in Q3 2019 and has held it in 21 quarters since.
  • Royal Bank of Canada's VistaGen Therapeutics position peaked at $85K in Q4 2021.
  • 48 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2026.

Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.